e-therapeutics plc (ETXPF)
- Previous Close
0.1300 - Open
0.1300 - Bid --
- Ask --
- Day's Range
0.1300 - 0.1300 - 52 Week Range
0.1300 - 0.2900 - Volume
10,000 - Avg. Volume
1,134 - Market Cap (intraday)
75.964M - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
www.etherapeutics.co.ukRelated News
Performance Overview: ETXPF
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETXPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETXPF
Valuation Measures
Market Cap
63.86M
Enterprise Value
33.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
175.54
Price/Book (mrq)
2.23
Enterprise Value/Revenue
97.92
Enterprise Value/EBITDA
-2.93
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.10%
Return on Equity (ttm)
-38.75%
Revenue (ttm)
340k
Net Income Avi to Common (ttm)
-10.06M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
24.84M
Total Debt/Equity (mrq)
0.33%
Levered Free Cash Flow (ttm)
-7.64M
Company Insights: ETXPF
ETXPF does not have Company Insights